浆细胞母细胞淋巴瘤（PBL）是一种弥散性大B细胞淋巴瘤（DLBCL）亚型，常伴有Epstein-Barr病毒（EBV）感染。尽管最近治疗方面取得了进展，但PBL的预后仍然不良。EBV被列为可能导致癌症的人类肿瘤病毒之一，与鼻咽癌（NPC）、淋巴瘤和10%的胃癌（GC）发生密切相关。探索EBV阳性和EBV阴性PBL之间不同表达的基因（DEGs）非常重要。通过对EBV阳性PBL和EBV阴性PBL之间的DEGs进行生物信息学分析，我们深入了解了EBV阳性PBL的发病机制。我们选择了GSE102203数据集，并筛选出EBV阳性PBL和EBV阴性PBL之间的DEGs。应用基因本体学（GO）和基因和基因组的京都百科全书（KEGG）进行分析。构建蛋白质-蛋白质相互作用（PPI）网络，并筛选出枢纽基因。最后，进行基因集富集分析（GSEA）。在EBV阳性PBL中，免疫相关通路被上调，且CD27和程序性细胞死亡配体1（PD-L1）是枢纽基因。在EBV阳性PBL中，EBV可能通过激活免疫相关通路和上调CD27、PD-L1来影响肿瘤发生。利用CD70/CD27和程序性细胞死亡1（PD-1）/PD-L1通路的免疫检查点阻滞剂可能是治疗EBV阳性PBL的有效策略之一。©2023。作者独家授权西班牙肿瘤学协会（FESEO）。

Plasmablastic lymphoma (PBL) is a subtype of diffuse large B-cell lymphoma (DLBCL) often associated with Epstein-Barr virus (EBV) infection. Despite recent advances in treatment, PBL still has a poor prognosis. EBV is listed as one of the human tumor viruses that may cause cancer, and is closely related to the occurrence of some nasopharyngeal carcinoma (NPC), lymphoma and 10% of gastric cancer (GC). It is very important to explore the differentially expressed genes (DEGs) between EBV-positive and EBV-negative PBL. Through bioinformatics analysis of DEGs between EBV-positive PBL and EBV-negative PBL, we gain a deeper understanding of the pathogenesis of EBV-positive PBL.We selected the GSE102203 data set, and screened the DEGs between EBV-positive PBL and EBV-negative PBL. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were applied. The protein-protein interaction (PPI) network was constructed, and screened for the hub genes. Finally, Gene Set Enrichment Analysis (GSEA) was performed.In EBV-positive PBL, the immune-related pathway is upregulated and Cluster of differentiation 27 (CD27) and programmed cell death-ligand 1 (PD-L1) are hub genes.In EBV-positive PBL, EBV may affect tumorigenesis through activation of immune-related pathways and upregulation of CD27, PD-L1. Immune checkpoint blockers of CD70/CD27 and programmed cell death 1 (PD-1)/PD-L1 pathways may be one of the effective strategies for the treatment of EBV-positive PBL.© 2023. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).